Economic and clinical impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada

Nazir J1, Wagg A2, Berling M3, McCrea C3, Faytoye F4, Ramos B5, Hakimi Z6

Research Type

Clinical

Abstract Category

Health Services Delivery

Abstract 564
Pelvic Pain and Urinary Tract Infection
Scientific Podium Short Oral Session 28
Friday 16th September 2016
14:52 - 15:00
Hall B5
Incontinence Mathematical or statistical modelling Outcomes Research Methods Overactive Bladder
1. Astellas Pharma Europe Ltd., Chertsey, UK, 2. University of Alberta, Edmonton, Canada, 3. Parexel International, London, UK, 4. Manchester Metropolitan University, Manchester, UK, 5. Astellas Pharma Canada Inc., Markham, Canada, 6. Astellas Pharma Europe B.V., Leiden, the Netherlands
Presenter
A

Adrian Wagg

Links

Abstract